Two phase I trials in patients with advanced EGFR-mutated NSCLC demonstrate promising potential of targeted therapy with amivantamab plus lazertinib

Positive in vitro and in vivo antitumour effects in breast and lung cancer models and in mismatch repair-driven cancer models

Significant, but clinically modest, prolongation of radiographic progression-free survival and event-free survival was achieved with darolutamide in the SAKK 08/16 study

Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer

Addition of abiraterone acetate plus prednisone shows clear survival improvements in castration-sensitive prostate cancer

Good response rate and disease control with adagrasib and sotorasib in combination therapy shown in early-stage trials

Results from the SAKK 01/10 trial demonstrate favourable progression-free survival and low toxicity with single-dose carboplatin and involved-node radiotherapy

Final overall survival results from the KEYNOTE-355 study confirm immune checkpoint inhibitors as the first-line treatment of choice in women with metastatic or relapsing disease

Too often the access to quality biomarkers is undermined by poor knowledge on the need for quality assurance. Relying on the assumption that biomarkers bring ‘innovation’ without claiming quality may be appealing to some, perhaps not really to medical conservatives – and not to patients, for sure.